AbbVie Agrees To Acquire Aliada Therapeutics For $1.4 Bln In Cash

October 28, 2024 — 08:19 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - AbbVie, Inc. (ABBV) and biotechnology company Aliada Therapeutics announced Monday a definitive agreement under which AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments.

Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aß) antibody in development for the treatment of Alzheimer's disease.

Aliada is advancing therapeutic candidates using its Modular Delivery (MODEL) platform, engineered for high-precision CNS drug delivery.

The acquisition allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience.

The transaction is expected to close in fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

AbbVie Agrees To Acquire Aliada Therapeutics For $1.4 Bln In Cash

Tags

Latest Articles